Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory
disease characterised by immune dysregulation affecting multiple organs. Current anti …

Background Systemic lupus erythematosus (SLE) is one of the most prevalent systemic
autoimmune diseases, and metabolic syndrome (MetS) is the most common metabolic …

Introduction It is well-documented that systemic lupus erythematosus (SLE) is associated
with dementia. However, the genetic causality of this association remains unclear …

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disorder with a prominent
genetic component. Evidence has shown that individuals of non–European ancestry …

Introduction At present, the treat-to-target approach has been proposed with the lupus low
disease activity state (LLDAS) as an achievable target. Objectives To determine damage …

Objective To estimate mortality and survival rates of SLE in a contemporary, population-
based setting and assess potential influences by time, sex, ethnicity, classification criteria …

Despite improvements in patient and renal death rates following the introduction of potent
immunosuppressive drugs in earlier decades, a sizeable fraction of patients with lupus …

Obesity, diabetes mellitus, and cardiovascular risk are real challenges in systemic lupus
erythematosus (SLE) clinical practice and research. The evidence of the burden of these …

Patients with systemic lupus erythematosus (SLE) are at increased risk of tuberculosis (TB)
infection due to immune dysfunction and immunosuppressive therapy. We present a case …